• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

双特异性抗体治疗肺癌的当前适应证和未来前景。

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.

机构信息

Medical Oncology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.

Oncobiona Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.

出版信息

Int J Mol Sci. 2023 Jun 7;24(12):9855. doi: 10.3390/ijms24129855.

DOI:10.3390/ijms24129855
PMID:37373003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10298459/
Abstract

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

摘要

双特异性抗体是一种很有前途的癌症治疗方法，因为它们能够同时抑制在癌症进展中发挥作用的不同蛋白。由于对潜在分子途径（特别是驱动肿瘤的癌基因）的认识越来越深入，肺癌的发展尤为迅猛。在这篇综述中，我们介绍了治疗肺癌的双特异性抗体的最新进展，并讨论了这些治疗药物在不久的将来可能扩大应用的潜在情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/10298459/223615fc4040/ijms-24-09855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/10298459/841ca6b0365b/ijms-24-09855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/10298459/223615fc4040/ijms-24-09855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/10298459/841ca6b0365b/ijms-24-09855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d4/10298459/223615fc4040/ijms-24-09855-g002.jpg

相似文献

1
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.双特异性抗体治疗肺癌的当前适应证和未来前景。
Int J Mol Sci. 2023 Jun 7;24(12):9855. doi: 10.3390/ijms24129855.
2
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.联合靶向 DLL3 的双特异性抗体与 PD-1 抑制可有效抑制小细胞肺癌生长。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000785.
3
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.双特异性免疫调节剂抗体在癌症免疫治疗中的应用
Clin Cancer Res. 2021 Oct 15;27(20):5457-5464. doi: 10.1158/1078-0432.CCR-20-3770. Epub 2021 Jun 9.
4
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.双特异性抗体在癌症免疫治疗中的现状和未来方向。
Front Immunol. 2022 Oct 28;13:1035276. doi: 10.3389/fimmu.2022.1035276. eCollection 2022.
5
Bispecific antibodies for cancer therapy.双特异性抗体在癌症治疗中的应用。
Immunotherapy. 2009 Mar;1(2):211-22. doi: 10.2217/1750743X.1.2.211.
6
Current status and future perspectives of bispecific antibodies in the treatment of lung cancer.双特异性抗体在肺癌治疗中的现状和未来展望。
Chin Med J (Engl). 2023 Feb 20;136(4):379-393. doi: 10.1097/CM9.0000000000002460.
7
[Advances in research of bispecific antibodies for antivirus therapy].[用于抗病毒治疗的双特异性抗体研究进展]
Sheng Wu Gong Cheng Xue Bao. 2019 Jul 25;35(7):1174-1183. doi: 10.13345/j.cjb.190040.
8
Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.酶化学合成岩藻糖基化双特异性纳米抗体作为癌症免疫治疗的双特异性抗体模拟物。
Angew Chem Int Ed Engl. 2022 Sep 19;61(38):e202208773. doi: 10.1002/anie.202208773. Epub 2022 Aug 17.
9
Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review.肺癌中的双特异性抗体：最新综述
Pharmaceuticals (Basel). 2023 Oct 14;16(10):1461. doi: 10.3390/ph16101461.
10
Recombinant bispecific antibodies for cellular cancer immunotherapy.用于细胞癌症免疫疗法的重组双特异性抗体。
Curr Opin Mol Ther. 2007 Aug;9(4):319-26.

引用本文的文献

1
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment.揭示协同潜力：双特异性抗体联合化疗治疗晚期非小细胞肺癌
Curr Oncol. 2025 Mar 31;32(4):206. doi: 10.3390/curroncol32040206.
2
Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.今日采用明日之疗法：肺癌过继性细胞疗法的前瞻性综述
Ther Adv Med Oncol. 2025 Feb 24;17:17588359251320280. doi: 10.1177/17588359251320280. eCollection 2025.
3
Daidzein Inhibits Non-small Cell Lung Cancer Growth by Pyroptosis.

本文引用的文献

1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.塔拉拉单抗，一种首创的 DLL3 靶向双特异性 T 细胞衔接器，用于复发性小细胞肺癌：一项开放标签、I 期研究。
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
2
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.度伐利尤单抗联合或不联合替西木单抗联合化疗作为转移性非小细胞肺癌一线治疗的 III 期 POSEIDON 研究。
J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.
3
大豆苷元通过细胞焦亡抑制非小细胞肺癌生长。
Curr Pharm Des. 2025;31(11):884-924. doi: 10.2174/0113816128330530240918073721.
4
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.肺癌中 PD-1/PD-L1 和 CTLA-4 的双重阻断免疫疗法。
J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2.
Camels' biological fluids contained nanobodies: promising avenue in cancer therapy.
骆驼的生物体液含有纳米抗体：癌症治疗的前景之路。
Cancer Cell Int. 2022 Sep 7;22(1):279. doi: 10.1186/s12935-022-02696-7.
4
Cadonilimab: First Approval.卡度尼利单抗：首次获批
Drugs. 2022 Aug;82(12):1333-1339. doi: 10.1007/s40265-022-01761-9.
5
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.在复发或难治性滤泡淋巴瘤患者中，双特异性抗体 mosunetuzumab 的安全性和疗效：一项单臂、多中心、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5.
6
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.替雷利珠单抗联合阿替利珠单抗对比安慰剂联合阿替利珠单抗作为 PD-L1 选择的非小细胞肺癌一线治疗（CITYSCAPE）：一项随机、双盲、II 期研究的主要和随访分析。
Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.
7
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.RET 驱动的肺和甲状腺癌中 RET 抑制剂耐药的演变。
Nat Commun. 2022 Mar 18;13(1):1450. doi: 10.1038/s41467-022-28848-x.
8
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
9
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.MARIPOSA：一线 amivantamab + lazertinib 对比奥希替尼用于 EGFR 突变非小细胞肺癌的 3 期研究。
Future Oncol. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16.
10
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.ALK重排非小细胞肺癌的耐药机制与治疗策略
Front Oncol. 2021 Oct 1;11:713530. doi: 10.3389/fonc.2021.713530. eCollection 2021.